Biomm SA
BOVESPA:BIOM3
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.1
20.19
|
| Price Target |
|
We'll email you a reminder when the closing price reaches BRL.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Biomm SA
Biomm SA
Other Operating Expenses
Biomm SA
Other Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biomm SA
BOVESPA:BIOM3
|
Other Operating Expenses
-R$3.7m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
2%
|
|
|
Blau Farmaceutica SA
BOVESPA:BLAU3
|
Other Operating Expenses
R$117.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
85%
|
CAGR 10-Years
N/A
|
|
Biomm SA
Glance View
BIOMM SA engages in the research, development, and manufacture of insulin. The company is headquartered in Nova Lima, Minas Gerais. The company went IPO on 2002-09-05. The firm is principally engaged in the development and licensing of technology for the production of human insulin and other recombinant proteins. The Company’s technology is suitable for the production of therapeutic proteins, which are used in the production of drugs and biopharmaceuticals. The Company’s technology for insulin production is protected by patents in various countries in Europe, Asia, North and South America. In addition, it is active in the development of production process of enzymes that are used in the hydrolysis of biomass and in the manufacture of bio-fuel. As of December 31, 2011, the Company’s subsidiaries were Biomm International Inc, Biomm Middle East Inc and Biomm Russia Ltd.
See Also
What is Biomm SA's Other Operating Expenses?
Other Operating Expenses
-3.7m
BRL
Based on the financial report for Jun 30, 2024, Biomm SA's Other Operating Expenses amounts to -3.7m BRL.
What is Biomm SA's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 10Y
2%
Over the last year, the Other Operating Expenses growth was 63%. The average annual Other Operating Expenses growth rates for Biomm SA have been -14% over the past three years , 15% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
